VRCA
HealthcareVerrica Pharmaceuticals Inc.
$8.87
+$0.57 (+6.87%)
Jan 5, 2026
Price History (1Y)
Analysis
Verrica Pharmaceuticals Inc. is a biotechnology company listed in the healthcare sector with a market capitalization of $141.83M and 71 employees. The company's financial health is characterized by a net income loss of -$26,014,000 and an EBITDA loss of -$14,958,000 over the trailing twelve months. The gross margin stands at 67.0%, while the operating margin is 11.3%. However, the profit margin is negative at -84.4%. The return on assets (ROA) is -26.3%. The company's balance sheet shows cash of $21.10M and debt of $35.74M. Verrica Pharmaceuticals Inc.'s valuation metrics include a forward P/E ratio of -3.76, price to book of -4.94, and EV/EBITDA of -6.25. The company's revenue over the trailing twelve months is $30.83M.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company's product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma; and VP-103, a cantharidin-based product candidate for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Visit website →Key Statistics
- Market Cap
- $141.83M
- P/E Ratio
- N/A
- 52-Week High
- $9.82
- 52-Week Low
- $3.28
- Avg Volume
- 309.88K
- Beta
- 1.46
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 71